VRDN earnings date and last-quarter result: last quarter miss, P/E -5.51. Updated 2026-07-23.
Viridian Therapeutics (VRDN) Research Hub
Viridian Therapeutics (VRDN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 23.34 USD (+4.34%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -5.51, market cap 1.70B. This hub links to the full technical, earnings and options research available for VRDN.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 23.34 USD (+4.34%) |
| 52-week range | 16.07 USD – 24.86 USD |
| Trend regime | Range |
| 14-day RSI | 80.7 (Overbought) |
| Trailing P/E | -5.51 |
| Market cap | 1.70B |
| Dividend yield | 0.00% |
Available research for VRDN
Covered Call on VRDN: how it works, illustrative setup around the real 23.34 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on VRDN: how it works, illustrative setup around the real 23.34 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on VRDN: how it works, illustrative setup around the real 23.34 USD price, max profit/loss, breakeven and when to use it. Educational.
VRDN technical analysis: range, last 23.34 USD, RSI 80.7, 52w range 16.07 USD–24.86 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is VRDN in?
Viridian Therapeutics (VRDN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is VRDN in an uptrend or downtrend?
As of 2026-10-26, VRDN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is VRDN's trailing P/E ratio?
VRDN's trailing P/E is -5.51, with a market cap of 1.70B. See the earnings research page for full valuation detail.